TriSalus Life Sciences Inc.
TLSI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TLSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TLSI
TriSalus Life Sciences Inc. is a commercial-stage medical device and immuno-oncology company focused on improving therapeutic delivery to solid tumors via its Pressure-Enabled Drug Delivery (PEDD) technology and the TriNav infusion system, while also developing the TLR9 agonist nelitolimod in early-stage clinical trials.
Key risk: Dependence on TriNav revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials for TriSalus Life Sciences Inc..
TriSalus Life Sciences Inc. is a commercial-stage medical device and immuno-oncology company focused on improving therapeutic delivery to solid tumors via its Pressure-Enabled Drug Delivery (PEDD) technology and the TriNav infusion system, while also developing the TLR9 agonist nelitolimod in early-stage clinical trials.
- TriSalus markets the TriNav infusion system, its sole commercial product, and is investing in sales and marketing to drive adoption and revenue growth [sec_mda · as of 2026-08-06].
- The company is developing nelitolimod, a TLR9 agonist acquired in July 2020, which has completed Phase I dose-escalation (UMLM, LA-PDAC) and Phase Ib (ICC/HCC) trials [sec_mda · as of 2026-03-05].
- As of June 30, 2026, TriSalus reported cash & equivalents of $46.3M, total revenue of $11.4M, net loss of $9.2M, and negative shareholders' equity of $33.9M [sec].
- The company does not intend to proceed to Phase II trials for nelitolimod in resectable colorectal liver metastases on its own and is seeking a pharmaceutical partner [sec_mda · as of 2026-08-06].
- TriSalus anticipates releasing a consolidated clinical update for nelitolimod in the second half of 2026 [sec_mda · as of 2026-08-06].
What works
- TriNav is a commercially approved device generating revenue, and the company believes it is a superior technology for delivering therapies to high-density tumors [sec_mda · as of 2026-05-12].
- Physician and investigator interest has led to two Investigator Initiated Trials of nelitolimod, indicating potential clinical utility [sec_mda · as of 2026-03-05].
- The company raised $42.6 million in net proceeds from a public offering and $0.3 million from an ESPP in the six months ended June 30, 2026, providing near-term funding [sec_mda · as of 2026-08-06].
What to weigh
- TriSalus has a history of net losses and negative shareholders' equity ($33.9M as of June 30, 2026), indicating ongoing financial challenges [sec].
- Nelitolimod is still in early-stage Phase 1 trials with no guarantee of favorable data or FDA approval, and the company has terminated prior Phase 1/2 studies [sec_mda · as of 2026-08-06] [catalyst].
- The company may need substantial additional funding to continue operations, and there is no assurance it can raise capital on satisfactory terms [sec_mda · as of 2026-03-05].
- TriSalus is dependent on the commercial success of a single product (TriNav) and faces risks from reimbursement, adoption, and competition [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
TriSalus has completed Phase I dose escalation and Phase Ib trials for nelitolimod.
“We have completed Phase I dose escalation (UMLM and LA-PDAC) and Phase Ib (ICC/HCC) clinical trials for nelitolimod.”
SEC MD&A · March 5, 2026
The company does not intend to proceed to Phase II for nelitolimod in resectable colorectal liver metastases alone and seeks a partner.
“Due to the excessive cost of capital, we do not intend to proceed to Phase II trials for that indication on our own, but we are looking for potential partners to advance that indication.”
SEC MD&A · August 6, 2026
TriSalus expects to release a consolidated clinical update in the second half of 2026.
“We anticipate releasing a consolidated clinical update in the second half of 2026 and will begin discussions for a pharmaceutical partner for further clinical development.”
SEC MD&A · August 6, 2026
The company's ability to fund operations depends on raising additional capital.
“Our ability to fund future operations and execute our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through the issuance of additional equity and/or debt.”
SEC MD&A · March 5, 2026
Risks & what to watch (4)›
Key risks
- Dependence on TriNav revenue — TriSalus relies on a single commercial product (TriNav) for revenue; failure to grow adoption or maintain reimbursement could materially impact operations [sec_mda · as of 2026-08-06].
- Early-stage drug pipeline — Nelitolimod is in Phase 1 trials with no guarantee of safety/efficacy or FDA approval; prior studies have been terminated [sec_mda · as of 2026-08-06] [catalyst].
- Need for additional funding — The company has negative shareholders' equity and may require substantial capital; no assurance of raising funds on acceptable terms [sec] [sec_mda · as of 2026-03-05].
- Clinical trial costs and uncertainty — Operating clinical trials for nelitolimod is costly with no guarantee of favorable data, and the company may need to delay or reduce programs if funding is insufficient [sec_mda · as of 2026-08-06].
What to watch
- Consolidated clinical update for nelitolimod expected in the second half of 2026 [sec_mda · as of 2026-08-06].
- Progress in partnering discussions for nelitolimod in resectable colorectal liver metastases [sec_mda · as of 2026-08-06].
- TriNav revenue growth and market adoption trends, as the company continues to invest in sales and marketing [sec_mda · as of 2026-08-06].
- Cash runway and any additional financing activities, given the company's negative equity and ongoing cash needs [sec] [sec_mda · as of 2026-03-05].
Sources: Catalysts · SEC MD&A · Generated August 19, 2026 · How we verify sources →
Run TriSalus Life Sciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TriSalus Life Sciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
14.9 months
D/E 8.53 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
6 buys · 15 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
81
Total value held
$46.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,694,072 | $10.8M |
| blackrock, inc. | 1,499,547 | $6.0M |
| wasatch advisors lp | 1,437,960 | $5.8M |
| gilder gagnon howe & co llc | 888,515 | $3.6M |
| geode capital management, llc | 777,094 | $3.1M |
| kennedy capital management llc | 485,242 | $1.9M |
| morgan stanley | 393,909 | $1.6M |
| state street corp | 328,020 | $1.3M |
| empire financial management company, llc | 300,275 | $1.2M |
| perkins capital management inc | 230,101 | $920K |
Showing top 10 of 81 institutional holders of TriSalus Life Sciences Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 11, 2026- % of float
- 2.8%
- Days to cover
- 7.3
- Shares short
- 1,323,315
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TLSI short interestGovernance
Frequently asked questions
What is the AI investment thesis for TriSalus Life Sciences Inc.?
TriSalus Life Sciences Inc. is a commercial-stage medical device and immuno-oncology company focused on improving therapeutic delivery to solid tumors via its Pressure-Enabled Drug Delivery (PEDD) technology and the TriNav infusion system, while also developing the TLR9 agonist nelitolimod in early-stage clinical trials.
What is TriSalus Life Sciences Inc.'s lead drug candidate?
TriSalus Life Sciences Inc.'s most advanced tracked candidate is nelitolimod (Phase 1) for uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.
Who is the CEO of TriSalus Life Sciences Inc.?
Ms. Mary T. Szela B.S.N., M.B.A. is the chief executive officer of TriSalus Life Sciences Inc. (TLSI).
Where is TriSalus Life Sciences Inc. headquartered?
TriSalus Life Sciences Inc. (TLSI) is headquartered in Westminster, CO, United States.
What therapeutic areas does TriSalus Life Sciences Inc. focus on?
TriSalus Life Sciences Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.